Print

Colby Pharmaceutical and MannKind Corporation (MNKD) Sign License and Joint Development Agreement to Develop and Commercialize Cancer Immunotherapy Products  
11/13/2012 9:32:17 AM

SAN JOSE, Calif. & VALENCIA, Calif.--(BUSINESS WIRE)--Colby Pharmaceutical Company and MannKind Corporation (Nasdaq: MNKD) today announced a license agreement granting Colby exclusive worldwide rights to develop and commercialize disease-specific antigen compounds and intra-lymph node delivery technologies from MannKind’s novel MKC1106 active immunotherapy programs, which are currently being developed for the treatment of melanoma, prostate, hematological disorders and other human cancers.
//-->